|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.44 CHF | -2.40% |
|
+0.92% | +22.54% |
| 03-12 | Swiss Market Index Extends Losses; Bachem Shares Jump | MT |
| 03-12 | Santhera Pharmaceuticals' FY25 Revenue Grows | MT |
| Capitalization | 215M 272M 238M 206M 374M 25.18B 389M 2.57B 1.02B 12.03B 1.02B 1B 43.46B | P/E ratio 2025 * |
-
| P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 215M 272M 238M 206M 374M 25.18B 389M 2.57B 1.02B 12.03B 1.02B 1B 43.46B | EV / Sales 2025 |
2.18x | EV / Sales 2026 * | 2.06x |
| Free-Float |
69.07% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Santhera Pharmaceuticals Holding AG
| 1 day | -2.40% | ||
| 1 week | +0.92% | ||
| Current month | -8.64% | ||
| 1 month | -5.28% | ||
| 3 months | +26.56% | ||
| 6 months | +4.47% | ||
| Current year | +22.54% |
| 1 week | 14.64 |  | 17.48 |
| 1 month | 14.64 | | 17.74 |
| Current year | 11.7 | | 17.74 |
| 1 year | 9.38 | | 17.74 |
| 3 years | 5.9 | | 17.76 |
| 5 years | 5 | | 34.9 |
| 10 years | 5 | | 863.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dario Eklund
CEO | Chief Executive Officer | 58 | 2019-11-30 |
Catherine Isted
DFI | Director of Finance/CFO | - | 2025-02-23 |
Marc Schrader
COO | Chief Operating Officer | - | 2022-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Meier
CHM | Chairman | 63 | 2022-06-29 |
| Director/Board Member | 58 | 2017-04-03 | |
Shabir Hasham
BRD | Director/Board Member | - | 2024-04-09 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.40% | +0.92% | +3.21% | +124.42% | 272M | |
| -1.51% | -2.13% | -19.79% | -36.53% | 53.62B | |
| +1.22% | +3.53% | +6.98% | -17.98% | 7.65B | |
| +0.16% | -5.51% | +4.26% | +48.36% | 7.51B | |
| -0.61% | -4.96% | -6.95% | +59.54% | 5.11B | |
| -0.60% | 0.00% | -17.52% | +104.44% | 4.92B | |
| -1.09% | -7.35% | +60.12% | +42.64% | 2.87B | |
| -0.69% | -1.73% | -12.45% | -21.49% | 2.64B | |
| -1.06% | -0.10% | +44.12% | +49.37% | 2.54B | |
| +2.63% | -0.32% | +356.78% | +526.63% | 2.53B | |
| Average | -0.40% | -0.72% | +41.87% | +87.94% | 8.97B | |
| Weighted average by Cap. | -0.87% | -1.50% | +0.63% | +7.14% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 70.61M 89.42M 78.16M 67.55M 123M 8.27B 128M 844M 334M 3.95B 336M 328M 14.27B | 104M 132M 115M 99.78M 181M 12.22B 189M 1.25B 494M 5.84B 496M 485M 21.08B |
| Net income | - | - |
| Net Debt | - | - |
Employees
79
Sector
Pharmaceuticals
Calendar
04-28 -
Earnings release - Annual 2025
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-03-13 | 15.44 CHF | -2.40% | 81,737 |
| 26-03-12 | 15.82 CHF | -7.16% | 197,234 |
| 26-03-11 | 17.04 CHF | +2.04% | 88,738 |
| 26-03-10 | 16.70 CHF | +5.03% | 128,811 |
| 26-03-09 | 15.90 CHF | +3.92% | 89,547 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
15.44CHF
Average target price
30.00CHF
Spread / Average Target
+94.30%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SANN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition